Overview

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Optimum Therapeutics, LLC
Treatments:
Carboplatin
Docetaxel
Suramin